Veradermics, Incorporated (MANE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $96.07: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Negative price momentum.
Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil tablet for pattern hair loss (PHL) affecting approximately 50 million men and 30 million women in the U.S. The company has no commercial revenue; it is... Read more
Sell if holding. Engine safety override at $96.07: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-14Recent Developments — Veradermics, Incorporated
Latest news
- NEWS This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga Jun 2, 2026 positive
- NEWS Needham Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $136 — benzinga Jun 2, 2026 positive
- NEWS Veradermics To Present Topline Results From Phase 2/3 '302' Study Of VDPHL01 At 2026 World Congress For Hair Research On — benzinga May 27, 2026 positive
- NEWS Veradermics To Present Two Comparative Analyses Of VDPHL01's Phase 2 Male Data Results Versus Published Data On Efficacy — benzinga May 14, 2026 positive
- NEWS Reported Earlier, Veradermics Prices Upsized Public Offering Of 3,843,790 Common Shares At $100 Per Share, Raising ~$384 — benzinga Apr 30, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelineVDPHL0110-K Item 1A: 'our success will substantially depend on the approval and successful commercialization of VDPHL01, which is our lead product candidate. If we are unable to obtain regulatory approval for, and successfully commercialize, VDPHL01...our business will be materially harmed'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $96.07: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $89.35. Score 5.3/10, moderate confidence.
Take-profit target: $112.41 (+17.0% upside). Prior stop was $89.35. Stop-loss: $89.35.
Concentration risk — Pipeline: VDPHL01; Quality below floor (2.5 < 4.0).
Veradermics, Incorporated trades at a P/E of N/A (forward -31.6). TrendMatrix value score: 7.5/10. Verdict: Sell.
10 analysts cover MANE with a consensus score of 4.4/5. Average price target: $132.
What does Veradermics, Incorporated do?Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil...
Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil tablet for pattern hair loss (PHL) affecting approximately 50 million men and 30 million women in the U.S. The company has no commercial revenue; it is conducting three pivotal registration-directed trials (two male PHL, one female PHL) funded by $557.8 million total equity proceeds including $294.8 million from its Q1 2026 IPO.